rj

@d_stock07734 @andrewcaravello Thanks for that! I hadn't seen this before. What I did see was a live shot of the ASCO 2022 booth for $NWBO #DCVax and I think Alice was there in-person. She's sitting at a table in the center of the photo wearing one of her trademark floral tops. ❤️

@sharpie510 @andrewcaravello Here is the picture.

$MRNA cancer vaccine just terminated in skin cancer. The trial enrolled 46 of a planned 412 patients, ended for “business reasons” with no efficacy data released. Here is why it failed, and why it was always going to fail in this population. The $MRNA approach (developed in partnership with $MRK, whose #Keytruda formed the checkpoint inhibitor arm of the terminated trial) sequences the patient’s tumor, identifies the unique mutations on the cancer cells, and packages those mutations into an #mRNA vaccine. When the patient gets the shot, the mRNA enters their own dendritic cells (the immune system’s teachers), which then translate the mRNA, display the tumor markers on their surface, and instruct T cells to find and kill cells carrying those markers. The mRNA is the lesson plan. The patient’s own dendritic cells are the teachers. The problem is the teachers. Most cancer patients are over sixty, and by that age the body’s teaching cells have largely gone quiet. Decades of inflammation have silenced the master gene (IRF8) that defines a functional teacher cell. A paper from Pittsburgh published this month showed that even in laboratory-prepared dendritic cells, only one in fifty to one in a hundred is actually capable of giving the immune system the right instruction. In the body of a person over sixty, the working fraction is even smaller. $MRNA delivered a perfect lesson plan to a classroom of teachers who can no longer teach. The students (CD4 helper and CD8 cytotoxic T cells) hear the lesson but get the wrong message, becoming tolerant or unresponsive instead of cytotoxic. There is a second problem the $MRNA approach cannot solve. Tumors mutate quickly. The first wave of T cells kills the cancer cells displaying the targeted markers. The cells that survive are the ones that learned to hide those markers. Within weeks, the tumor escapes. This is the escape variant problem that has limited every targeted cancer therapy from CAR-T forward. Two weeks before $MRNA termination, Dr. Pawel Kalinski at the University of Pittsburgh gave a public lecture explaining exactly why this approach would fail and what the solution looks like. His platform manufactures the teacher cells outside the body, in a clean environment where the silencing has not occurred, then sorts for the rare productive subset that actually produces the instructional signal at full strength. The CD4 and CD8 T cells these manufactured teachers educate recognize cancer cells through two mechanisms instead of one: the specific tumor marker AND a stress signal (NKG2D recognizing MIC-A) that cancer cells cannot easily hide from both recognition systems at once. Escape variants get caught by the second recognition system. In his clinical work, this approach produced complete or near-complete responses in seven of nine breast cancer patients in a recent trial. $NWBO owns this platform. Their #DCVax dendritic cell vaccine is built on Kalinski’s technology, manufactured under license from Pittsburgh and Roswell Park. The forward extension Kalinski’s lab is now developing pairs the manufactured teacher with the patient’s own T cells in a closed bioreactor where the teaching signal is delivered correctly, then potentially infuses both the teacher and the educated students back into the patient. The teacher would establish a permanent immune outpost at the injection site. The students would travel through the body and find cancer cells through the dual-recognition system that no current cancer therapy uses. $MRNA model: deliver the lesson plan, hope the teachers can still teach. $NWBO model: build the teacher, deliver the working teacher with the lesson plan already inside, let the working teacher do the instructing. When the teachers in the patient’s body have gone quiet, only one of these models works. Two weeks ago Kalinski explained why. This week $MRNA confirmed it.

@stephanieseneff Meanwhile: x.com/sharpie510/sta… #t=2185.968" target="_blank" rel="nofollow noopener">vimeo.com/273334745?shar…

A major setback for mRNA cancer vaccine technology. A closely watched phase 2/3 trial of Moderna's product to treat cutaneous squamous cell carcinoma was prematurely terminated, without revealing the reasons for aborting the trial. trialsitenews.com/a/moderna-and-…

Northwest Biotherapeutics: $NWBO My top pick into end of 2026. Super high risk (8/10) but potential for multi-bagger.

"Among the innovative brain tumor vaccines, DCVax-L has shown the most clinical promise, achieving a median overall survival of 22.2 months in Phase III trials through personalized DC activation." FreezeYourTumor GetDCVax #gbm #glioblastoma $nwbo #dcvax thieme-connect.com/products/ejour…

May 7, 2026 UCLA researchers help lead national effort to improve care for patients with #glioblastoma 💪 New Department of Defense-funded collaboration aims to improve treatment monitoring and accelerate more personalized therapies 👍 $nwbo #dcvax #gbm uclahealth.org/news/release/u…

Treatment #18 of 28 today. Just 10 more proton sessions to go. Then… London. Today we officially received confirmation of Braelyn’s pre-apheresis and leukapheresis appointments in the UK for DCVax immunotherapy. This is getting real. We are excited. We are nervous. We are hopeful. Today was also her second Avastin infusion. Some moments today were hard. The fatigue is real. The hair loss is accelerating. Radiation swelling continues to affect her speech and cognition at times. But she still finds ways to smile at me between all of it. I know these aren’t the best photos - she doesn’t always cooperate when I want to take her picture. But this is what fighting looks like sometimes. Exhaustion. Courage. Humor. Fear. Hope. All in the same room. And somehow, despite everything, we are now only weeks away from beginning the next phase we fought so hard to reach. June 1st. London. DCVax process begins! One day at a time. 💜 #BrainCancerAwarenessMonth #Glioblastoma #GBM #DCVax #DCvaxForBraelyn #ProtonTherapy #GrayMatterMatters

Patients need to know a #glioblastoma diagnosis does not have to be a death sentence. 🙏 BeProactive FreezeYourTumor GetDCVax QualityOfLifeMatters #gbm #BrainCancerAwarenessMonth $nwbo #dcvax

@ThomasOwenMcCa1 Happy 50th Birthday, Thomas!

May 6th 2026 was my 50th birthday 🎂! (photo credit my son Jake). It was a huge milestone for me, not only did I celebrate my 11th anniversary of being administered the DCVax in March. I never thought I’d make it to 50, especially celebrating with my family. I’m very grateful to so many people who played a vital role in keeping me here. Dr. Linda Liau, Dr. Timothy Cloughesy, Nanette Fong, My family, my friends, F.O.G. However even though I’m a long tail survivor, I’m sure there are many Doctors still dismissing this scientific breakthrough in personalized immunotherapy. To them I say, the proof is in the pudding, I’m not an anomaly. I’m not a one off… I’m thriving, living my life with gratitude, & grace. I KNOW THAT NWBO’s DCVax WILL BE APPROVED. & there is little any Big Pharma executive or MARKET MAKER ON WALL ST. Can do about it. Sorry Kenneth C. Griffin your greed & political donations won’t save you, a wave 🌊 is coming for you… @kshaughnessy2 @LisainNJUSA @HollensbeAmanda @nprpolitics @NorthwestBio @ElvirPons @NHSEnglandLDN @MHRAgovuk @NYMag @TheLastWord @LastWeekTonight @latimes @LAmag

Why is this not available to everyone, I dont know how many fundraiser I have seen the past years for #dcvax @MHRAgovuk $NWBO newsandstar.co.uk/news/26077923.…

#BrainCancerAwarenessMonth 2026. Here are just a few of the patients that got non-toxic #DCVax-L for #glioblastoma #gbm.I believe ALL ARE STILL LIVING LIFE, many already exceeding 13-20+ years with NO RECURRENCE. $nwbo 💪 BeProactive FreezeYourTumor GetDCVax QualityOfLifeMatters

@TomBaxers I've already shared it with a few friends that might be interested in a quick update on where NWBO currently stands. For them, a podcast is doable, as they can listen to it while commuting.

@sharpie510 Agreed, the info is sound. I got bored halfway through and gave up on it. I dont have an issue either, just that it isn't a real podcast with real live podcasters per-se.

BeProactive FreezeYourTumor GetDCVax QualityOfLifeMatters youtu.be/bEzGquPLRM4?si… #glioblastoma #gbm $nwbo #dcvax

@TomBaxers If the information is sound, I don't have an issue with it.

@sharpie510 AI generated podcast.

May is Brain Cancer Awareness Month. These shirts help fund Braelyn's DCVax treatment and raise awareness. Go Gray for Braelyn. “…Because Gray Matter Matters.” BeProactive FreezeYourTumor GetDCVax QualityOfLifeMatters #gbm #glioblastoma $nwbo #dcvax instagram.com/p/DX5by0nlQOW/

$MMAT | In re Meta Materials Inc. (Ch. 7) | Case No. 24-50792-gs 📄 Filing: Reply to Citadel’s Response re: Litigation Funding Agreement 📅 Filed: April 30, 2026 📑 Doc No.: 2751 ⚠️ Not Legal Advice ⸻ 🧠 Layman’s Breakdown This is the Trustee (Lovato) pushing back hard on Citadel trying to block or question the litigation funding. 👉 Simple version (paraphrasing): The Trustee is saying: “Citadel shouldn’t even be allowed to object… and we need this funding to go after potential claims.” She argues: Litigation funding = necessary fuel to investigate and bring cases No risk to the estate if the case fails Citadel is stalling and hasn’t produced data for over a year ⸻ 🔥 Standout Quotes “Citadel… lacks standing to oppose” 👉 Translation: They don’t even have the legal right to be arguing here. ⸻ “More than a year later, Citadel has refused to produce any information.” 👉 That’s a direct shot—accusing Citadel of delaying discovery. 💥 ⸻ “Without a litigation funding source, the Trustee would be unable to investigate… or prosecute… claims.” 👉 Funding = required to even bring cases ⸻ “The greatest risk is with… the litigation funder.” 👉 Estate risk = minimal 👉 Funders/lawyers take the hit if it fails ⸻ “Citadel’s only argument is that the Estate should not have funds…” 👉 That’s a very sharp framing: They don’t want us to have the money to investigate them ⸻ “Claims would languish and likely lose value [without funding].” 👉 Time pressure = real (ties to statute of limitations) ⸻ ⚖️ What This Means for the 5/7/2026 Hearing 📌 This filing does 3 important things: 1. Frames Citadel as an outsider “No standing” Judge may: Discount or ignore Citadel’s objections entirely 2. Emphasizes urgency (August 2026 deadline) Trustee is signaling: “We are running out of time to bring claims” 👉 Judges take that seriously 3. Positions funding as essential—not optional Without funding: No investigation No lawsuits No recovery 👉 This strengthens approval under business judgment standard dropbox.com/scl/fi/s9ikriy…

UCLA AANHPI Heritage Month: Stories, research and voices from across campus | UCLA Hannah Fox May 1, 2026 BeProactive FreezeYourTumor GetDCVax QualityOfLifeMatters #gbm #glioblastoma $nwbo #dcvax newsroom.ucla.edu/stories/in-foc…

@hoffmann6383 ATLnsider on iHub found that the deal between Cannacord and Cantor did in fact close on November 7, 2025 (see page 23). So this deal did not influence them to settle; something else did. $nwbo #dcvax canaccordgenuity.com/4abe42/globala…

➡️A Settlement $NWBO The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) The Docket: courtlistener.com/docket/6657959… Recall, when I stated Canaccord Genuity was selling their market making division to Cantor and that could lead to a settlement as they would want to clean up before selling? See: x.com/hoffmann6383/s… Well, it happened. Just like TD settled their spoofing lawsuit prior to their Schwab sale. Here is $NWBO's recent court filing showing they have reached a settlement with Canaccord Genuity: See attached image. This should give $NWBO an infusion of cash. As a public company we should keep an eye on upcoming 10Q/10K filings to get an idea of the settlement amount.

@SouthernDrive21 investorshub.advfn.com/boards/read_ms… $nwbo #dcvax #glioblastoma #gbm

$NWBO prnewswire.com/news-releases/… "NWBO appointed Dr. Annalisa Jenkins as a Strategic Adviser to help advance and expand the company’s DCVax dendritic-cell cancer vaccine platform. The release emphasizes her background in global R&D, regulatory strategy, commercialization, biotech financing, and prior leadership roles at Merck Serono, Bristol-Myers Squibb, and Dimension Therapeutics" Dr. Jenkins served as President and CEO of Dimension Therapeutics, a leading gene therapy company that she took public on NASDAQ and subsequently sold to Ultragenyx.